Corectim

Introduction

Corectim (Delgocitinib) is a Janus kinase (JAK) inhibitor, a cream containing 0.5% Delgocitinib as the main ingredient.

Effects

Delgocitinib has an inhibitory effect on JAK1, JAK2, JAK3 and tyrosine kinase 2. In the preclinical study Chemicalbook, topical application of delgocitinib inhibited skin inflammation, improved skin barrier dysfunction, and inhibited itch caused by IL-31.

On January 23, 2020, Corectim® Delgocitinib (コレクチム® Ointment 0.5%), jointly developed by Japan’s JT (Tobacco) and Torii Pharmaceutical, was approved by the Pharmaceutical and Medical Devices Agency (PMDA) under the Ministry of Health, Labor and Welfare of Japan for the topical treatment of mild to moderate atopic dermatitis (atopic) in adults (≥16 years old) dermatitis, AD) (eczema, eczema).

This is the world’s first topical JAK drug for the treatment of atopic dermatitis. For adult patients ≥16 years old, the recommended dose is topical application twice a day, and the amount applied should not exceed 5g each time.

For moderate to severe atopic dermatitis, the phase 3 QBA4-1 clinical trial (VS placebo): the primary endpoint of the percentage change from baseline in mEASI score was significantly better than placebo.